ASCO updates stage IV NSCLC guidance, adding repotrectinib and zongertinib, with trial-backed dosing and sequencing tips for ...
The single-arm trial met its primary end point of complete response (CR) at any time, exceeding historic and contemporary ...
New KRAS-targeting drug for metastatic pancreatic cancer nearly doubles second-line survival; expert explains impact, side effects, next trials.
Chromosome 13q linkage promotes RB1 hemizygosity during BRCA2 LOH, lowering the ‘two-hit’ barrier and predisposing to ...
Community oncology improves hereditary cancer care by expanding risk assessment, dense-breast and polyp screening, plus ...
An investigator behind gedatolisib's FDA approval discusses the trial data, dosing, and adverse effects shaping HR+/HER2- ...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 in favor of the IGNYTE study (NCT03767348) supporting the potential accelerated approval of vusolimogene oderparepvec (RP1; ...
Dr. Monty Pal discusses the growing importance of quality of life and long-term tolerability when selecting subsequent ...
Betts, MD, discusses how PTCy and tacrolimus protocols, as well as using younger donors, contributes to higher survival rates ...
Objective response rate was 35% (3 CR, 3 PR), with most patients demonstrating primary progression despite meeting ...
MCED screening and broader genetic testing push community oncology toward prevention—learn how practices adapt workflows, ...
Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results